BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome. J Pharmacol Sci 2019;139:46-9. [PMID: 30522964 DOI: 10.1016/j.jphs.2018.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Okumura T, Nozu T, Ishioh M, Igarashi S, Kumei S, Ohhira M. Centrally administered butyrate improves gut barrier function, visceral sensation and septic lethality in rats. J Pharmacol Sci 2021;146:183-91. [PMID: 34116731 DOI: 10.1016/j.jphs.2021.04.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
2 Roudsari NM, Lashgari NA, Zandi N, Pazoki B, Momtaz S, Sahebkar A, Abdolghaffari AH. PPARγ: A turning point for irritable bowel syndrome treatment. Life Sci 2020;257:118103. [PMID: 32681913 DOI: 10.1016/j.lfs.2020.118103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome. Neurogastroenterol Motil 2020;32:e13819. [PMID: 32056324 DOI: 10.1111/nmo.13819] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
4 Wang J, Zhang X, Yang C, Zhao S. Effect of monoacylglycerol lipase inhibition on intestinal permeability in chronic stress model. Biochem Biophys Res Commun 2020;525:962-7. [PMID: 32173532 DOI: 10.1016/j.bbrc.2020.02.173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
5 López-gómez L, Bagüés A, Uranga JA, Abalo R. Preclinical models of irritable bowel syndrome. A Comprehensive Overview of Irritable Bowel Syndrome. Elsevier; 2020. pp. 233-76. [DOI: 10.1016/b978-0-12-821324-7.00012-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Sci Rep 2019;9:19603. [PMID: 31862976 DOI: 10.1038/s41598-019-56132-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
7 d'Angelo M, Castelli V, Tupone MG, Catanesi M, Antonosante A, Dominguez-Benot R, Ippoliti R, Cimini AM, Benedetti E. Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs. Int J Mol Sci 2019;20:E5422. [PMID: 31683535 DOI: 10.3390/ijms20215422] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hong F, Pan S, Guo Y, Xu P, Zhai Y. PPARs as Nuclear Receptors for Nutrient and Energy Metabolism. Molecules 2019;24:E2545. [PMID: 31336903 DOI: 10.3390/molecules24142545] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 19.3] [Reference Citation Analysis]
9 Klepsch V, Moschen AR, Tilg H, Baier G, Hermann-Kleiter N. Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD. Front Immunol 2019;10:1070. [PMID: 31139192 DOI: 10.3389/fimmu.2019.01070] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]